In conclusion, dysregulated SPP1/HMOX1 expression was strongly related to glioma WHO grades and worse outcomes, providing deeper insights into glioma therapeutic targets and oncolytic virus‐based treatments. The gene discussed is HMOX1; the disease is central nervous system cancer.